Search research articles
Contact Us
Filters
Showing results (31-40 of 60) with videos related to
Page
of 6
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
March 15, 2024
PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma
Ludek Pour, Ilina Micheva, Ganna Usenko, et al.
European Journal of Haematology
|
November 28, 2015
Prospective study of signalling pathways in myeloma bone disease with regard to activity of the disease, extent of skeletal involvement and correlation to bone turnover markers
Jiri Minarik, Zuzana Hermanova, Pavla Petrova, et al.
Genomics
|
July 9, 2013
Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia
Fedor Kryukov, Elena Dementyeva, Lenka Kubiczkova, et al.
Annals of Hematology
|
March 8, 2011
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma
Marta Krejci, Evzen Gregora, Jan Straub, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 29, 2026
BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function
Ludek Pour, Sosana Delimpasi, Wojciech Legiec, et al.
Scientific Reports
|
July 20, 2021
Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities
Eva Kriegova, Regina Fillerova, Jiri Minarik, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 25, 2022
Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data
Vladimir Maisnar, Ludek Pour, Ivan Spicka, et al.
Biomedicines
|
October 27, 2022
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
Martin Stork, Sabina Sevcikova, Tomas Jelinek, et al.
British Journal of Haematology
|
November 2, 2021
Identification of patients at high risk of secondary extramedullary multiple myeloma development
Martin Stork, Sabina Sevcikova, Jiri Minarik, et al.
BMC Cancer
|
April 9, 2025
Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
Jiri Minarik, Ludek Pour, Vojtech Latal, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 60) with videos related to
Sort By:
Page
of 6
Clinical Lymphoma, Myeloma & Leukemia
|
March 15, 2024
PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma
Ludek Pour, Ilina Micheva, Ganna Usenko, et al.
European Journal of Haematology
|
November 28, 2015
Prospective study of signalling pathways in myeloma bone disease with regard to activity of the disease, extent of skeletal involvement and correlation to bone turnover markers
Jiri Minarik, Zuzana Hermanova, Pavla Petrova, et al.
Genomics
|
July 9, 2013
Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia
Fedor Kryukov, Elena Dementyeva, Lenka Kubiczkova, et al.
Annals of Hematology
|
March 8, 2011
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma
Marta Krejci, Evzen Gregora, Jan Straub, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 29, 2026
BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function
Ludek Pour, Sosana Delimpasi, Wojciech Legiec, et al.
Scientific Reports
|
July 20, 2021
Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities
Eva Kriegova, Regina Fillerova, Jiri Minarik, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 25, 2022
Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data
Vladimir Maisnar, Ludek Pour, Ivan Spicka, et al.
Biomedicines
|
October 27, 2022
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
Martin Stork, Sabina Sevcikova, Tomas Jelinek, et al.
British Journal of Haematology
|
November 2, 2021
Identification of patients at high risk of secondary extramedullary multiple myeloma development
Martin Stork, Sabina Sevcikova, Jiri Minarik, et al.
BMC Cancer
|
April 9, 2025
Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
Jiri Minarik, Ludek Pour, Vojtech Latal, et al.
Page
of 6